PSMA

Synonyms

EC:3.4.17.21, GIG27, Glutamate carboxypeptidase II, NAALADase I, FOLH, Cell growth-inhibiting gene 27 protein, PSM, N-acetylated-alpha-linked acidic dipeptidase I, GCPII, Folylpoly-gamma-glutamate carboxypeptidase, Folate hydrolase 1, FOLH1, Pteroylpoly-Gamma-Glutamate Carboxypeptidase, Membrane Glutamate Carboxypeptidase, Glutamate Carboxypeptidase 2, Glutamate Carboxylase II, NAALAD1, FGCP, PSMA, MGCP, Folate Hydrolase (Prostate-Specific Membrane Antigen) 1, N-Acetylated Alpha-Linked Acidic Dipeptidase 1, Prostate Specific Membrane Antigen Variant F, Prostate-Specific Membrane Antigen, EC 3.4.17.21, NAALAdase, GCP2,

KO Status

F0

Drug Information

Launched drugs: 20
Drugs in clinical trials: 2
Latest Research Phase:Approved

Drug Name

Code

Phase

Company

Indications

Clinical Trials

MIP-1375

MIP-1375, 131-I-MIP-1375

Preclinical

Progenics Pharmaceuticals Inc

Prostatic Neoplasms

Capromab pendetide

CYT-356, 111In CYT-356, lndium-CYT-356, Indium-111-CYT-356

Approved

Eusa Pharma

Prostatic Neoplasms

Gallium-68 PSMA-11

Ga-68-PSMA-11, Ga-68-PSMA

Approved

Radiomedix

Prostatic Neoplasms

[18F]DCFPyL

Phase 3 Clinical

Johns Hopkins University

Carcinoma, Renal Cell, Prostatic Neoplasms

177Lu-PSMA-R2

177Lu-PSMA-R2, 177Lu-PSMA-SR6

Phase 2 Clinical

Advanced Accelerator Applications

Prostatic Neoplasms

4SCAR-PSMA T cell therapy (Shenzhen Geno-Immune Medical Institute)

Phase 2 Clinical

Shenzhen Geno-Immune Medical Institute

Neoplasms

Df-IA2BM-Zr-89

IAB2M, 89Zr-Df-IAB2M, Df-IA2BM-Zr-89, 64Cu-NODAGA-PSMA-Mb

Phase 2 Clinical

Imaginab

Prostatic Neoplasms, Glioma

HPN-424

HPN-424

Phase 2 Clinical

Harpoon Therapeutics

Prostatic Neoplasms

89Zr-DFO-huJ591

Zr89-J591, 89Zr-DFO-J591, 89Zr-DFO-huJ591

Phase 2 Clinical

Memorial Sloan Kettering Cancer Center

Prostatic Neoplasms

[131I]MIP-1095

1095, [131I]MIP-1095, [131I]MIP-1466

Phase 2 Clinical

Progenics Pharmaceuticals Inc

Prostatic Neoplasms

ATL-101 (ATLAB)

J-591, MLN-591, huJ-591, muJ-591, 90Y-J591, MLN-591RL, 177Lu-J591, Lu-177-J591

Phase 2 Clinical

Cornell University

Prostatic Neoplasms

INO-5401

INO5401, INO-5401

Phase 2 Clinical

Inovio

Glioblastoma, Carcinoma, Transitional Cell

Anti-PSMA CAR T-cell therapy (TNK Therapeutics)

Phase 1 Clinical

Sorrento Therapeutics

Neoplasms

MOR-209/ES414

APVO-414, MOR-209, ES-414

Phase 1 Clinical

Emergent

Prostatic Neoplasms

AMG-160

AMG-160

Phase 1 Clinical

Amgen Inc

Prostatic Neoplasms, Castration-Resistant, Prostatic Neoplasms

INO-5150

INO-5150

Phase 1 Clinical

Inovio

Prostatic Neoplasms

Autologous T-cell therapy (anti-PSMA-CD3), Roger Williams Medical Center

Phase 1 Clinical

Roger Williams Medical Center

Prostatic Neoplasms

CART-PSMA-TGFbRDN (University of Pennsylvania)

Phase 1 Clinical

University Of Pennsylvania

Prostatic Neoplasms

PSMA-CART cell therapy (Shanghai Bioray Laboratory)

Phase 1 Clinical

Shanghai Bioray Laboratory Inc

Prostatic Neoplasms

CC-1

CC-1

Phase 1 Clinical

The University Of Tubingen, Deutsches Krebsforschungszentrum, Dkfz

Prostatic Neoplasms